Last reviewed · How we verify
NCT05384743
Rituximab Monotherapy for EBV-HLH and CAEBV
Phase 3 trial testing Rituximab Monotherapy in Secondary Hemophagocytic Lymphohistiocytosis in 30 participants. Status unknown.
1 February 2024
Quick facts
| Lead sponsor | Beijing Friendship Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 February 2022 |
| Primary completion | 1 February 2024 |
| Estimated completion | 1 April 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Rituximab Monotherapy — full drug profile →
Conditions studied
- Secondary Hemophagocytic Lymphohistiocytosis — all drugs for Secondary Hemophagocytic Lymphohistiocytosis →
- Chronic Active Epstein-Barr Virus Infection — all drugs for Chronic Active Epstein-Barr Virus Infection →
Sponsor
Beijing Friendship Hospital
Who can join
Adults 2 to 80, any sex, with Secondary Hemophagocytic Lymphohistiocytosis or Chronic Active Epstein-Barr Virus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a prospective single-arm clinical study, focusing on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis and Chronic Active Epstein-Barr Virus Infection with only and mainly B lymphocytes of EBV infection, to evaluate the clinical efficacy of Rituximab in the treatment of EBV-HLH and CAEBV.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms.
Wu Y, Sun X, Kang K, Yang Y, et al · · 2024 · cited 47× · PMID 39511607 · DOI 10.1186/s13045-024-01621-x -
Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis/macrophage activation syndrome: a translational perspective.
Nguyen TTT, Kim YT, Jeong G, Jin M. · · 2024 · cited 26× · PMID 38448692 · DOI 10.1038/s12276-024-01182-6 -
Secondary hemophagocytic lymphohistiocytosis in children (Review).
Benevenuta C, Mussinatto I, Orsi C, Timeus FS. · · 2023 · cited 10× · PMID 37602304 · DOI 10.3892/etm.2023.12122 -
Role of rapidly evolving immunotherapy in chronic active Epstein-Barr virus disease.
Yan S, Ming X, Zhu X, Xiao Y. · · 2024 · cited 5× · PMID 39691713 · DOI 10.3389/fimmu.2024.1451977
Verify or expand the search:
- PubMed search for NCT05384743
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Secondary Hemophagocytic Lymphohistiocytosis
Currently open trials in the same condition.
- NCT06339177 — Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study · recruiting
Other Beijing Friendship Hospital trials
Trials by the same sponsor.
- NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
- NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
- NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
- NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
- NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05384743 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
- Last refreshed: 20 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05384743.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing